About: Rasagiline

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rasagiline Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B430B-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4308-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4309-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B430A-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Weinreb O, Amit T, Bar-Am O, Youdim MB: RASAGILINE; A NOVEL ANTI-PARKINSONIAN MONOAMINE OXIDASE-B INHIBITOR WITH NEUROPROTECTIVE ACTIVITY. Prog Neurobiol. 2010 Jun 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20600573 # Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20517484 # Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18035186 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B. (en)
http://linked.open...ugbank/indication	For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa. (en)
sameAs	Rasagiline Rasagiline
Title	Rasagiline (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/bindingdb/10989 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/chemspider/2314553 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/drugbank/DB01367 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/kegg-drug/D02562 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/national-drug-code-directory/68546-142-56 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pdb/RAS http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pubchem-compound/3052776 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pubchem-substance/46506045 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/pharmgkb/PA164764584 http://linked.opendata.cz/resource/drugbank/drug/DB01367/identifier/wikipedia/Rasagiline
http://linked.open...mechanismOfAction	The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction. (en)
http://linked.open...drugbank/packager	Golden State Medical Supply Inc. H and H Laboratories
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2031714 http://linked.opendata.cz/resource/drugbank/patent/2232310 http://linked.opendata.cz/resource/drugbank/patent/5387612 http://linked.opendata.cz/resource/drugbank/patent/7572834
http://linked.open...outeOfElimination	Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. Glucuronide conjugation of rasagiline and its metabolites, with subsequent urinary excretion, is the major elimination pathway. After oral administration of 14C-labeled rasagiline, elimination occurred primarily via urine and secondarily via feces (62% of total dose in urine and 7% of total dose in feces over 7 days), with a total calculated recovery of 84% of the dose over a period of 38 days. Less than 1% of rasagiline was excreted as unchanged drug in urine. (en)
http://linked.open.../drugbank/synonym	RAS (en) (1R)-N-Propargylindan-1-amine (en) (R)-Indan-1-yl-prop-2-ynyl-amine (en) (R)-N-2-Propynyl-1-indanamine (en)
http://linked.open...drugbank/toxicity	Signs and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. (en)
http://linked.open...umeOfDistribution	* 87 L (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/28-92-00
http://linked.open...k/foodInteraction	Avoid alcohol and caffeine. (en)
http://linked.open...nk/proteinBinding	Plasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/ml. (en)
http://linked.open...ynthesisReference	Jeffrey Sterling, David Lerner, Harel Rosen, Leonid Bronov, Dalia Medini-Green, Berta Iosefzon, Tirtsah Berger-Peskin, Ramy Lidor-Hadas, Eliezer Bahar, "Rasagiline formulations and processes for their preparation." U.S. Patent US07598420, issued October 06, 2009. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0100095
foaf:page	http://www.drugs.com/cdi/rasagiline.html http://www.rxlist.com/cgi/generic/azilect.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4310-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4316-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4315-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4312-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4313-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4314-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B430E-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B430F-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B430C-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B430D-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Rasagiline
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B431C-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B431D-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4317-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4318-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B431A-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4319-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B431B-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rasagiline is rapidly absorbed following oral administration. The absolute bioavailability of rasagiline is about 36%. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	136236-51-6 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Azilect 0.5 mg tablet Apo-Metoprolol (Type L) 50 mg Tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4321-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4323-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4324-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4320-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B431F-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4322-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4311-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B431E-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software